PROM1 and myocardial infarction: We sought to determine the functional consequencesand clinical events that followed direct intramyocardialdelivery of autologous bone marrow-derived MNCs andCD133+ cells in MI patients in this phase II/III multicenter,randomized, double-blind, placebo-controlled study.Findings from a comparison of CD133+ cells or MNCsversus placebo in the COMPARE CPM-RMI (CD133,Placebo, MNCs)-(recent myocardial infarction) trial haveimplications for the development of cell-based therapiesfor ischemic heart failure.